Track Algorae Pharmaceuticals Limited's common stock ($85M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
Algorae Pharmaceuticals Limited posts a common stock of $85M as of June 2026. That compares with $82M in the prior-year period — up 4.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Algorae Pharmaceuticals Limited's common stock was $82M. The latest reading is $85M — a 4.7% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.
Common Stock is one piece of Algorae Pharmaceuticals Limited's financial statement story. At $85M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for LVCLF's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Algorae Pharmaceuticals Limited's other metric pages and overview cover the third.
Judging Algorae Pharmaceuticals Limited against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in common stock easier to interpret. Start with $85M here, then scan peer and history charts to see if the gap is persistent.